Is the Flu Shot Necessary? What the Evidence Says

Seasonal flu vaccination prevents millions of cases of influenza each year and substantially reduces hospitalizations and deaths, but how well it works in any given season depends on how closely the vaccine matches the viruses actually circulating. In a well-matched year, the shot cuts your risk of needing medical care for flu by roughly 40 to 60 percent; in a poorly matched year, that number can drop to single digits. That variability is the main reason the flu shot provokes more skepticism than, say, the measles vaccine, where effectiveness barely budges from year to year. The evidence, though, shows that even in a mediocre year the shot confers benefits most people don’t associate with a flu vaccine at all.

Why Effectiveness Swings So Much From Year to Year

Influenza viruses mutate constantly. Their surface proteins shift just enough between seasons that last year’s immunity, whether from vaccination or from getting sick, often only partially recognizes this year’s strain. This process, called antigenic drift, happens most often in H3N2 strains, followed by influenza B and then H1N1.

Vaccine makers pick which strains to include months before flu season starts, based on global surveillance data. When they guess right, protection is solid. When the virus drifts after that decision is locked in, effectiveness drops. The 2019–2020 U.S. season is a stark example: early in the season the vaccine worked reasonably well against B/Victoria viruses, but by late season, antigenically drifted H1N1 viruses had emerged. Against those late-season strains, the vaccine offered essentially no measurable protection, with effectiveness estimated at just 7 percent.¹ That is well below the historically observed range of 40 to 60 percent for H1N1.

A separate analysis of Hong Kong surveillance data spanning 16 years confirmed that genetic mismatch between vaccine strains and circulating viruses is common and is the primary driver of season-to-season swings in how well the vaccine works.² So the honest answer to “does the flu shot work?” is: it depends on the year, and you won’t know until the season is underway.

There is a second, subtler manufacturing problem. Most flu vaccines are still grown in chicken eggs, and the virus can pick up mutations during that process that change the very surface proteins the vaccine is supposed to teach your immune system to recognize. One well-documented egg-adaptive mutation, called L194P, has been shown to alter the antigenic properties of the H3N2 hemagglutinin protein enough to reduce how well the vaccine works.³ Cell-based and recombinant vaccines sidestep this issue, but egg-grown vaccines still make up a large share of global supply.

Protection Fades During the Season

Even in a good-match year, the protection you get from a flu shot is not static. Antibody levels typically peak about a month after vaccination and then decline over the following months.⁴ One large study found that every additional four weeks after vaccination raised the odds of testing positive for flu by about 16 percent. By five months out, the odds of testing positive had roughly doubled compared with someone vaccinated just two to six weeks earlier.⁵

This creates a timing dilemma. Get vaccinated too early, say August, and your protection may be running low by the time flu peaks in January or February. Wait too long, and you risk catching the flu before you’re vaccinated. A simulation study focused on older adults found that delaying vaccination until October could backfire if more than about 14 percent of people who would have gotten their shot in August or September ended up skipping it altogether.⁶ For most people, September or October hits the sweet spot between too early and too late.

The Cardiovascular Bonus

One of the strongest and least appreciated arguments for the flu shot has nothing to do with avoiding a week of misery in bed. Influenza infection triggers inflammation throughout the body, and that inflammatory surge can destabilize arterial plaques, promote blood clotting, and stress the heart. Multiple pooled analyses of clinical trials have found that flu vaccination significantly lowers the risk of major cardiovascular events like heart attacks and strokes.

A meta-analysis of randomized trials reported that vaccinated patients experienced about a 34 percent lower risk of major cardiovascular events compared with those receiving placebo, with roughly 3.6 percent of vaccinated patients having an event versus 5.4 percent of controls.⁷ Another systematic review that included both trials and observational studies in people with existing cardiovascular disease found that vaccination was linked to a 25 percent lower risk of dying from any cause and an 18 percent lower risk of dying specifically from cardiovascular causes over a median follow-up of about 19 months.⁸ A third meta-analysis looking specifically at clinical trials found a risk ratio of 0.70 for major cardiovascular events in the vaccinated group.⁹

For someone who already has heart disease, the flu shot may be one of the most cost-effective medical interventions available, right alongside statins and blood-pressure medications. Clinical guidelines now specifically recommend annual flu vaccination for people with cardiovascular disease.

How Well It Works for Children

Children are one of the main engines of flu transmission. They shed the virus longer than adults, spend hours together in classrooms, and are not especially conscientious about hand hygiene. The vaccine tends to work well in this age group. A large study covering five flu seasons in the U.S. estimated that receiving at least one dose of flu vaccine was about 56 percent effective at preventing flu-related emergency department visits or hospitalizations in children of all ages. Protection was similar across severity levels: roughly 53 percent for ED visits, 52 percent for non-critical hospitalizations, and 50 percent for critical hospitalizations.¹⁰

What makes those numbers particularly relevant is that vaccination in children confers protection to people around them. An agent-based modeling study estimated that increasing vaccination rates in school-aged children by just 5 to 15 percent could reduce symptomatic flu cases across all age groups by roughly 3 to 12 percent, potentially averting up to nearly 50,000 U.S. hospitalizations per year, with the largest benefit falling on adults 65 and older.¹¹ A separate household study found that vaccinating children roughly halved the probability that unvaccinated adult household contacts would get infected, though community transmission remained the dominant route of exposure for adults overall.¹²

Pregnancy and Infant Protection

Pregnant women face higher risks of severe flu complications because pregnancy suppresses parts of the immune system and increases cardiac and respiratory demands. Vaccination during pregnancy reduces rates and severity of illness in the mother and also passes antibodies to the baby.¹³ A study measuring antibody levels in cord blood found that babies born to vaccinated mothers had significantly higher H1N1-specific antibodies at birth than babies of unvaccinated mothers, with the transfer ratio more than double. Vaccination during the second or third trimester produced the strongest cord blood responses.¹⁴

Inactivated flu vaccines are considered safe and well-tolerated in pregnancy. Clinical guidelines recommend that all pregnant women receive an inactivated quadrivalent influenza vaccine from the second trimester onward.¹⁵ This is one population where the risk-benefit calculation is especially clear: the mother gets direct protection, and the baby gets a few months of passive immunity covering the period before they are old enough to be vaccinated themselves.

Older Adults and Immune Aging

The immune system becomes less responsive with age, which is why standard flu vaccines tend to work less well in people over 65. The standard-dose shot can still prevent illness, but the antibody response it generates is often weaker and fades faster than in younger adults. This has led to the development of enhanced vaccines for older adults, including high-dose formulations and adjuvanted vaccines that include ingredients designed to provoke a stronger immune response.

Research suggests that these enhanced formulations can overcome much of the deficit caused by immune aging. A review of data on both standard and enhanced vaccines noted that with the appropriate formulation, including adjuvants or higher antigen doses, vaccine-induced protection can actually exceed the protection provided by natural infection.¹⁶ If you are over 65, the type of flu vaccine you receive matters at least as much as whether you receive one at all. Ask for a high-dose or adjuvanted option rather than assuming all flu shots are interchangeable.

Safety Concerns and the Guillain-Barré Question

The most commonly cited serious safety concern around the flu vaccine is Guillain-Barré syndrome, a rare condition where the immune system attacks the peripheral nerves, causing weakness and sometimes paralysis. An epidemiological review found that the evidence does suggest a small elevated risk of GBS after flu vaccination, but that risk is considerably lower than the risk of developing GBS after a natural influenza infection.¹⁷ In other words, skipping the vaccine to avoid GBS risk actually increases your overall GBS risk if you end up catching the flu.

Common side effects of the flu shot, like a sore arm, mild fatigue, or low-grade fever, are signs of the immune system responding, not signs of illness. The vaccine cannot give you the flu. Inactivated vaccines contain no live virus, and the nasal spray vaccine uses a weakened form that can replicate in the cooler temperatures of the nasal passages but not in the lungs. Some people develop mild cold-like symptoms after the nasal spray, but that is not influenza.

The Economic Case

From a public health perspective, flu vaccination is one of the more cost-effective interventions available. A European estimate found that at current vaccination rates, seasonal flu shots prevent between 1.6 and 2.1 million cases, 45,000 to 66,000 hospitalizations, and 25,000 to 37,000 deaths annually across EU countries. If vaccination coverage reached the 75 percent target set by the EU, those numbers would climb substantially, with an additional 1.6 to 1.7 million cases averted and nearly 900,000 to over a million additional lost workdays prevented each year.¹⁸

A U.S. simulation study estimated that expanding vaccination access through pharmacies could avert nearly 12 million symptomatic influenza cases and over 23,000 deaths per season, generating over 5 billion dollars in savings when accounting for healthcare costs, lost productivity, and premature death.¹⁹ The convenience factor alone, being able to walk into a pharmacy without an appointment, moves the needle on coverage in a meaningful way.

What Nudges Actually Work to Increase Uptake

Knowledge about flu vaccine benefits is necessary but not sufficient to get most people vaccinated. A large systematic review of behavioral interventions found that the two most effective strategies were a direct recommendation from a healthcare provider and offering vaccination on site, both of which roughly tripled the odds of someone getting vaccinated.²⁰ A randomized trial in adults over 50 tested a multicomponent nudge that combined clinician prompts with patient reminders and found that vaccination during a primary care visit rose from about 26 percent in the standard-care group to about 31 percent in the nudge group, a modest but real 5-percentage-point increase.²¹

Even a simple letter mailed to Medicare beneficiaries significantly raised vaccination rates compared to no letter at all, though different versions of the letter tailored with various psychological techniques all performed about equally.²² The takeaway is that the biggest barrier for many people is not opposition to the vaccine but inertia. Making it easy and making sure someone suggests it go a long way.

Why Natural Immunity Is Not a Reliable Alternative

Some people argue they would rather “let their immune system handle it” than get vaccinated. Natural infection does generate an immune response, and one study estimated that getting the flu reduced the risk of reinfection by about 15 percent.²³ But that modest protection comes at the price of actually being sick, with real risks of pneumonia, hospitalization, missed work, and transmission to vulnerable people around you. And because the virus mutates so quickly, last year’s natural infection often does not protect you well against this year’s circulating strains, for the same antigenic drift reasons that complicate vaccine design.

There is also a concept in immunology sometimes called “original antigenic sin,” where your immune system’s first encounter with a flu strain shapes how it responds to future strains for life. Early exposures bias the immune system toward certain targets, which can be either helpful or unhelpful depending on which strains come along later.²⁴ This immunological baggage affects both vaccinated and unvaccinated people, but it means the romantic notion of “training” your immune system by catching the flu is more complicated than it sounds.

The Flu During the COVID Era

The overlap of flu and COVID-19 seasons added an additional reason to get vaccinated. Being infected with both viruses simultaneously is not just theoretically possible; it happens with enough regularity that researchers have studied its consequences. A study of co-infected patients found that carrying both influenza and SARS-CoV-2 at the same time was associated with worse outcomes, including greater severity and higher mortality, compared with COVID alone.²⁵ Preventing flu through vaccination removes one of those two threats from the equation.

Morning Shots and Other Practical Details

A curious finding from a cluster-randomized trial: people vaccinated in the morning produced a significantly stronger antibody response to two of the three vaccine strains compared with people vaccinated in the afternoon.²⁶ The immune system appears to follow circadian rhythms that make it more responsive earlier in the day. This is not a reason to skip a flu shot because you can only get to the pharmacy at 4 PM, but if you have the choice, scheduling a morning appointment may squeeze out a little extra protection.

Regarding the type of vaccine, the standard inactivated shot and the nasal spray (live attenuated) vaccine generate somewhat different immune responses. The inactivated shot produces higher levels of circulating blood antibodies, while the nasal spray tends to generate stronger local immune responses in the nasal passages and airways.²⁷ In adults, the inactivated shot generally performs better because adults have pre-existing immunity that limits how well the live attenuated virus can replicate in the nose.²⁸ In children, the nasal spray has the added benefit of boosting cross-reactive T cells that can recognize even flu strains not included in the vaccine, and these cells persist for at least six months.²⁹

Universal Flu Vaccines on the Horizon

The annual guessing game of strain matching has motivated decades of work on a universal influenza vaccine, one that would protect against many or all strains and would not need to be updated every year. The most promising approach targets the stem region of the hemagglutinin protein, which is highly conserved across different flu subtypes while the head region (the part current vaccines target) keeps changing. T cells directed at conserved viral proteins also contribute to cross-strain protection by limiting how much the virus can replicate and reducing disease severity even when antibodies don’t fully block infection.³⁰

Several mRNA-based universal flu vaccine candidates are now in development, using the same lipid nanoparticle platform that proved successful with COVID-19 vaccines. One such candidate, designed to encode the hemagglutinin stem antigen from H1N1, showed protective efficacy against both H1 and H5 influenza A viruses in animal models.³¹ Other candidates combine the hemagglutinin stem with nucleoprotein to stimulate both antibody and T-cell responses, and have been tested in non-human primates with encouraging immunogenicity results.³² These are still in early stages, but a workable universal vaccine would transform flu prevention from an annual gamble into something closer to a one-and-done intervention.

Influenza pandemics have emerged roughly every 40 years on average over at least five centuries of recorded history. The seasonal vaccine infrastructure built to handle ordinary flu seasons also serves as the backbone of pandemic preparedness. Annual vaccination keeps manufacturing capacity primed, surveillance networks active, and public familiarity with the process high enough that scaling up during a pandemic is at least logistically feasible. Abandoning that infrastructure during interpandemic years would leave the world considerably more vulnerable when the next novel strain emerges.